In situ follicular lymphoma In situ follicular lymphoma has also been termed follicular lymphoma in situ; follicular lymphoma of B cells of undetermined significance; intrafollicular neoplasia/in situ follicular lymphoma; in situ localization of follicular lymphoma; incipient follicular lymphoma; and follicular lymphoma of compartmentalized follicular central cells. The disorder involves an accumulation of monoclonal B-cells in the germinal centers of<unk>  tissue. These B-cells commonly bear a translocation between position 32 on the long (i.e. "q") arm of chromosome 14 and position 21 on chromosome 18's q arm. This same t(14:18)q32:q21) translocation is a genetic hallmark of FL and juxtaposes the B-cell lymphoma 2 (BCL2) gene on chromosome 18 at position q21.33 with the immunoglobulin heavy chain locus (IGH@) on chromosome 14 at position q21. In consequence, BCL2 overexpresses its product, BCL2 apoptosis regulator (i.e. Bcl2). Blc2 functions to inhibit programmed cell death thereby prolonging cell survival. The overexpression of Bcl2 in the B-cells of ISFL is thought to be a critical factor in their pathological accumulation and subsequent malignant progression. Small numbers (e.g. 1 in 100,000) of circulating blood cells bearing the t(14:18)q32:q21) translocation are found in 50-67% of otherwise healthy individuals. The prevalence of this finding increases with age, tobacco smoking, pesticide exposure, and race (50-70% in Caucasians, 10-20% in Japanese individuals). Since most individuals with this translocation in their blood cells do not develop ISFL or FL, t(14:18)(q32:q21), while prolonging cell survival, must be just one step in the development of these disorders. The translocation is proposed to occur during the early development of immature bone marrow B-cells (i.e. pre-B-cells/pro-B-cells) after which these cells circulate freely and in rare cases accumulate in the germinal centers of<unk>  follicles to form ISFL. The mechanism(s) favoring this localization and accumulation is unclear. Up to 6% of the individuals with ISFL progress to FL. This progression may involve the acquisition of other genomic aberrations in the ISFL B-cells such as mutations in the following genes: 1) EZH2 (encodes polycomb repressive complex 2 family protein which is involved in maintaining the transcriptional repressive state of various genes and is found in up to 27% of FL cases); 2) CREBBP (encodes CREB-binding protein which contributes to the activation of various genes); 3) TNFSF14 (encodes tumor necrosis factor superfamily member 14, a member of the tumor necrosis factor superfamily which may function as a co-stimulatory factor for the activation of<unk>  cells); and 4) KMT2D (encodes histone-lysine N-methyltransferase 2D, a histone methyltransferase which regulates the expression of various genes). ISFL may also acquire numerous copy-number variations (i.e. duplications and deletions of a portion of a chromosome along with any of the genes contained therein) that may contribute to FL. In all cases, the number of genetic abnormalities acquired in the B-cells of ISFL are much less than those in FL. In situ mantle cell neoplasia In situ mantle cell neoplasia has also been termed in situ involvement by MCL-like cells and in situ-like B-cells of uncertain significance. The disorder involves the accumulation of monoclonal B-cells in the inner layer of the mantel zone of<unk>  follicles. In most cases of ISFL, these B-cells bear a translocation between position 13 on the q arm of chromosome 11 and position 32 on chromosome 14's q arm. This t(11:14)q13:q32) translocation, which is a hallmark found in most cases of MCL, juxtaposes the CCND1 gene at position 13.3 on the q arm of chromosome 11 with the IGH@ locus on chromosome 14 at position q21. In consequence, CCND1 overexpresses cyclin D1, a protein which promotes the cell cycle and thereby cellular proliferation. The overexpression of cyclin D1 is thought to be a major factor in the development of ISMCL and its progression to MCL. Extremely low numbers of circulating blood cells that bear the t(11:14)q13:q32) translocation occur in 1-8% of healthy individuals. While the role of these cells in causing ISMCL has not been clarified, it is suggested that, similar to the events in the development of ISFL, this translocation occurs in bone marrow pre-B-cells/pro-B-cells after which the cells circulate freely and in rare cases accumulate in the mantle zone of<unk>  follicles to form ISMCL and thereafter MCl. Development of ISMCL and MCL from bone marrow and circulating B-cells bearing the t(14:18)q32:q21) transformation is much less common than the development of ISFL from bone marrow and circulation ISFL cells bearing the t(11:14)q13:q32) translocation, perhaps because the overexpression of cyclin D2 is weaker than Bcl2 overexpression in driving cells to accumulate and become malignant. The progression of ISMCL to MCL appears to involve the acquisition of other genetic alterations in ISMCL B-cells. Deletions and mutations of TP53 (located on the short (i.e. "p") arm of chromosome 17 at position p13.1 (i.e. at 17p13.1 and encoding a tumor suppressor protein); CDKN2Aand CDKN2A (both located at 9p21.3 and respectively encoding cyclin dependent kinase inhibitor 2A and cyclin dependent kinase inhibitor 2B which regulate the cell cycle); RB1 (located at 13q14.2 and encoding the tumor suppressor and cell cycle regulator, retinoblastoma 1 ); and ATM (located at 11q22.3 and encoding ATM serine/threonine kinase, a kinase that regulates the activity of various tumor suppressors and cell cycle proteins). It may also involve gains in the expression of MYC and BMI1 (encoding the c-Myc and B lymphoma Mo-MLV insertion region 1 homolog proto-oncogenes). However, the roles of these gene products is uncertain because there are scores of other genetic abnormalities in MCL that could contribute to the progression of ISMCL to MCL.
In situ lymphoid neoplasia
Benign lymphoepithelial lesion
Germ cell neoplasia in situ
Solitary lymphatic nodule
Intraepithelial neoplasia
Squamous intraepithelial lesion
Ductal carcinoma in situ
Epithelial dysplasia